Affordable Access

Septic cardiomyopathy - A not yet discovered cardiomyopathy?

Authors
  • Muller-Werdan, Ursula
  • Buerke, Michael
  • Ebelt, Henning
  • Heinroth, Konstantin M
  • Herklotz, Anja
  • Loppnow, Harald
  • Ruß, Martin
  • Schlegel, Frithjof
  • Schlitt, Axel
  • Schmidt, Hendrik B
  • Söffker, Gerold
  • Werdan, Karl
Type
Published Article
Journal
Experimental and clinical cardiology
Publication Date
Jan 01, 2006
Volume
11
Issue
3
Pages
226–236
Identifiers
PMID: 18651035
Source
Medline
Keywords
License
Unknown

Abstract

Myocardial depression in human sepsis was only unequivocally proven in the 1980s by the group of Parrillo, who used nuclear imaging techniques to measure heart volumes and function in intensive care patients. Heart failure in sepsis is frequently masked by a seemingly normal cardiac output. However, relative to the lowered systemic vascular resistance - resulting in a reduced afterload - cardiac outputs and ventricular ejection fractions are often not adequately enhanced. This septic cardiomyopathy (impairment of the heart within the scope of systemic sepsis) involves both the right and the left ventricles, and is potentially reversible. In response to volume substitution, the heart can be considerably enlarged. The cardiomyopathy is not primarily hypoxic in nature, but may be aggravated by ischemia. Autonomic dysfunction, documented by a reduced heart rate variability and impaired baroreflex and chemoreflex sensitivities, forms part of the disease entity. The severity of myocardial depression correlates with a poor prognosis. Noninfectious systemic inflammatory response syndrome can give rise to an analogous disease entity, namely, systemic inflammatory response syndrome cardiomyopathy.The etiology of septic cardiomyopathy is multifactorial. Several candidates with a potential pathogenetic impact on the heart were identified: bacterial toxins; cytokines and mediators including tumour necrosis factor-alpha, interleukin-1 and nitric oxide; cardiodepressant factors; oxygen reactive species; and catecholamines. Symptomatic treatment consists of volume substitution and catecholamine support; causal therapeutic approaches aiming at an interruption of the proinflammatory mediator cascades are being tested.

Report this publication

Statistics

Seen <100 times